Characteristics | n | % |
---|---|---|
Age (years) | Â | Â |
 < 54 | 108 | 53.2 |
 ≥ 54 | 95 | 46.8 |
FIGO stage | Â | Â |
 IIa | 14 | 6.9 |
 IIb | 105 | 51.7 |
 IIIa | 8 | 3.9 |
 IIIb | 75 | 36.9 |
 IVa | 1 | 0.5 |
Infection | Â | Â |
 Yes | 15 | 7.4 |
 No | 188 | 92.6 |
Anemia | Â | Â |
 Yes | 80 | 39.4 |
 No | 123 | 60.6 |
Lymph node metastasis | Â | Â |
 Yes | 57 | 28.1 |
 No | 146 | 71.9 |
TDpre* (cm) | Â | Â |
 ≤ 4.4 | 88 | 43.3 |
 > 4.4 | 115 | 56.7 |
TVpre* (cm3) | Â | Â |
 ≤ 45.71 | 105 | 51.7 |
 > 45.71 | 98 | 48.3 |
TDpost* (cm) | Â | Â |
 ≤ 2.4 | 127 | 62.6 |
 > 2.4 | 76 | 37.4 |
TVpost* (cm3) | Â | Â |
 ≤ 10.45 | 137 | 67.5 |
 > 10.45 | 66 | 32.5 |
TVRR* (%) | Â | Â |
 < 80.1 | 78 | 38.4 |
 ≥ 80.1 | 125 | 61.6 |
Radiotherapy | Â | Â |
 IMRT | 123 | 60.6 |
 CRT | 80 | 39.4 |
Total dose of radiotherapy (Gy) | Â | Â |
 ≤ 84 | 107 | 52.7 |
 > 84 | 96 | 47.3 |
Number of chemotherapy cycles | Â | Â |
 < 4 | 65 | 32.0 |
 ≥ 4 | 138 | 68.0 |
SCCpre (µg/L) |  |  |
 ≤ 11.4 | 145 | 71.4 |
 > 11.4 | 58 | 28.6 |
SCCpost (µg/L) |  |  |
 ≤ 1.9 | 180 | 88.7 |
 > 1.9 | 23 | 11.3 |
SCCRR (%) | Â | Â |
 = 100 | 122 | 60.1 |
 < 100 | 24 | 11.8 |